Evidence Summary
- Evidence Level
- Moderate
- Mechanism
- Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Unknown / General
- Safety
- Infusion reactions, serious infections (including PML risk), hepatitis B reactivation, hypogammaglobulinemia. Requires specialist oversight, screening, monitoring.
- Dosing
- Typical rheumatology regimens 1000 mg IV x2 (2 weeks apart) or 375 mg/m² weekly x4; ME/CFS trials used similar; repeat as needed.
Anti-CD20 studied in ME/CFS (mixed prior). Several trials. Serious infection risk. Specialist use only for clear autoimmune subsets. 5 trial associations.
Clinical Trials
5 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT06952413 | Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) | Phase 2 | Recruiting |
| NCT01156922 | B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome | Phase 2 | Terminated |
| NCT02229942 | B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. | Phase 3 | Completed |
| NCT00848692 | Drug Intervention in Chronic Fatigue Syndrome | Phase 2 | Completed |
| NCT01156909 | B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome | Phase 2 | Completed |
Key Studies / References
- See linked studies